Envestnet Portfolio Solutions Inc. Sells 2,578 Shares of Natera, Inc. (NASDAQ:NTRA)

Envestnet Portfolio Solutions Inc. lowered its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 24.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,838 shares of the medical research company's stock after selling 2,578 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Natera were worth $1,108,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of NTRA. LRI Investments LLC purchased a new stake in Natera during the fourth quarter valued at approximately $29,000. Rakuten Securities Inc. increased its stake in shares of Natera by 117.8% in the first quarter. Rakuten Securities Inc. now owns 220 shares of the medical research company's stock worth $31,000 after purchasing an additional 119 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Natera by 223.7% in the fourth quarter. Blue Trust Inc. now owns 301 shares of the medical research company's stock worth $48,000 after purchasing an additional 208 shares in the last quarter. EverSource Wealth Advisors LLC increased its stake in shares of Natera by 372.9% in the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock worth $52,000 after purchasing an additional 261 shares in the last quarter. Finally, Principal Securities Inc. increased its stake in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Institutional investors own 99.90% of the company's stock.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 9,563 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $1,323,614.83. Following the sale, the chief executive officer now owns 212,541 shares of the company's stock, valued at $29,417,799.81. This trade represents a 4.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Michael Burkes Brophy sold 2,562 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $354,606.42. Following the sale, the chief financial officer now directly owns 75,557 shares in the company, valued at approximately $10,457,844.37. The trade was a 3.28% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 59,755 shares of company stock worth $8,898,589. Insiders own 7.60% of the company's stock.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $171.87 on Wednesday. The firm has a market cap of $23.47 billion, a PE ratio of -116.92 and a beta of 1.74. The firm has a fifty day moving average of $157.84 and a 200 day moving average of $158.54. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00.

Natera (NASDAQ:NTRA - Get Free Report) last released its earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $0.09. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The business had revenue of $501.83 million during the quarter, compared to analyst estimates of $446.68 million. During the same quarter in the prior year, the firm earned ($0.56) earnings per share. The company's revenue for the quarter was up 36.5% compared to the same quarter last year. On average, equities analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NTRA. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Royal Bank Of Canada began coverage on shares of Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price objective for the company. Barclays increased their price objective on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a research note on Friday, May 9th. BTIG Research restated a "buy" rating on shares of Natera in a research report on Friday, February 28th. Finally, Robert W. Baird raised their target price on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research note on Friday, February 28th. One equities research analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.